Antonella Padella

Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Lactobacillus rhamnosus GG Administration Is Associated with Stimulation of Vitamin D/VDR Pathway and Mucosal Microbiota Modulation in Ulcerative Colitis Patients: A Pilot Study.

Lactobacillus rhamnosus GG Administration Is Associated with Stimulation of Vitamin D/VDR Pathway and Mucosal Microbiota Modulation in Ulcerative Colitis Patients: A Pilot Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 22, 2025

Correction to: Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Correction to: Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Journal: Cell biology and toxicology

Published: August 31, 2024

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.

Journal: Journal of translational medicine

Published: July 09, 2024

Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients.

Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients.

Journal: Frontiers in cellular and infection microbiology

Published: December 07, 2023

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.

Journal: Journal of hematology & oncology

Published: November 15, 2021

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

Journal: Cancers

Published: August 19, 2021

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Journal: Cell biology and toxicology

Published: April 14, 2021

Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.

Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.

Journal: Frontiers in oncology

Published: March 23, 2021

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.

Journal: Leukemia

Published: March 11, 2021

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.

Journal: Biomedicines

Published: March 01, 2021

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.

Journal: Cancer research

Published: November 10, 2020

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.

Journal: Minerva medica

Published: September 21, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026